ClinicalTrials.gg
CompletedNCT06360445Updated Apr 11, 2024

Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects

A Phase 1 interventional study of Olaparib Tablet test formulation 100mg and Olaparib Tablet reference formulation 100mg in Healthy Participants, sponsored by CSPC Ouyi Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-11.

Sponsored by CSPC Ouyi Pharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled May 2022, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

This Study is a Randomized, Open-Label, 2-formulation, Single-Dose, 2-Period Crossover Bioequivalence Study with a washout period of 7 days. During each session, the subjects were administered a single dose of 100 mg Olaparib Tablets (Test formulation or reference formulation ) under Fasting conditions or 150mg Olaparib Tablets (Test formulation or reference formulation ) under Fasting and Fed conditions. Venous blood samples were collected at pre-dose (0 h), and up to 72 h post dose. This study was to evaluate the bioequivalence and safety of the test formulation and the reference formulation of Olaparib Tablets in healthy subjects.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

CSPC Ouyi Pharmaceutical Co., Ltd. is the lead sponsor of 30 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants were fully aware of the purpose, character, methodology, and possible adverse effects of the trial, and signed an form prior to the initiation of any research procedures;
  2. Healthy male aged 18 to 50 years old (including critical values);
  3. Weight equal to or more than 50.0 kg and between 19 to 26.0 kg/m\^2 (including critical values);
  4. Participants had no history of chronic or serious diseases, including cardiovascular, respiratory, gastrointestinal, urinary, hematologic and lymphatic, endocrine, immune, psychiatric, or neurological system diseases;
  5. Participants whose immediate family members had no breast, ovarian, pancreatic, prostate cancer, and other related diseases;
  6. Normal or abnormal results without clinical significance on all tests including vital signs, physical examination, laboratory evaluation (hematology, urinalysis, blood biochemistry, serology, coagulation function, and urine drug screening), 12-lead , chest X-ray /Chest Computed Tomography (CCT) and alcohol breath test;
  7. Voluntarily signed the informed consent form, and cooperated in completing the trial according to the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Allergic constitution or allergic history to drugs or food;
  2. Participants with tablet swallowing distress;
  3. Participants with a history of surgery or trauma that may affect safety or in vivo metabolism of the drug, or who had undergone surgery within 1 year prior to screening or who were scheduled to undergo surgery during the trial;
  4. Participants who had used potent CYP 3A4 strong inhibitors, CYP 3A4 moderate inhibitors, CYP 3A4 strong inducers, and CYP 3A4 moderate inducers within 4 weeks prior to screening;
  5. Participants who had used p-gp inhibitors within 4 weeks prior to screening;
  6. Participants who had used any medicines or health products within 2 weeks prior to screening,
  7. Participants with a history of drug or substance abuse within 6 months prior to screening,or a positive urine drug test during screening;
  8. Participants who had used drugs within 3 months prior to screening;
  9. Smoking ≥ 5 cigarettes per day on average within 3 months prior to screening,or participants who could not stop using any tobacco-based products during the trial period;
  10. Participants who consumed more than 14 units of alcohol per week within the 3 months prior to screening, or who had a positive breath test for alcohol at screening,or who could not abstain from alcohol during the trial ;
  11. Participants who consumed excessive amounts of tea, coffee and/or caffeine-rich beverages per day within 3 months prior to screening
  12. Participants who had taken a special diet (dragon fruit, mango, grapefruit, lime, star fruit or food or drink prepared from them) within 7 days prior to screening, or participants who were unable to stop taking the above special diets during the trial;
  13. Participants who had participated in other clinical trials within 3 months prior to screening;
  14. Participants who had lost blood or donated more than 400 ml of blood or who had received blood transfusions or used blood products within 3 months prior to screening;
  15. Participants who cannot tolerate venipuncture or with a history of fainting needle or blood;
  16. Participants who are lactose intolerant;
  17. Participants with special dietary requirements who could not accept a uniform diet;
  18. Participants who were planning to have children, unwilling or unable to use effective , or had a plan to donate sperm from 2 weeks prior to the screening until 6 months after the last dose of study drug, and who were unwilling to use non-pharmacological contraception from 2 weeks prior to the screening until one month after the last dose of study drug;
  19. Any condition that the investigator considered inappropriate for participation in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Olaparib Tablet test formulation 100mg

    Treatment A: During the study session, healthy subjects were administered a single dose of Olaparib Tablet test formulation100mg under Fasting conditions(test)

    Drug: Olaparib Tablet test formulation 100mg

  • Active comparator
    Olaparib Tablet reference formulation 100mg

    Treatment B: During the study session, healthy subjects were administered a single dose of Olaparib Tablet reference formulation 100mg under Fasting conditions(reference for Treatment A)

    Drug: Olaparib Tablet reference formulation 100mg

  • Experimental
    Olaparib Tablet test formulation 150mg(fast)

    Treatment C: During the study session, healthy subjects were administered a single dose of Olaparib Tablet test formulation 150mg under Fasting conditions(test)

    Drug: Olaparib Tablet test formulation 150mg

  • Active comparator
    Olaparib Tablet reference formulation 150mg(fast)

    Treatment D: During the study session, healthy subjects were administered a single dose of Olaparib Tablet reference formulation 150mg under Fasting conditions(reference for Treatment C)

    Drug: Olaparib Tablet reference formulation 150mg

  • Experimental
    Olaparib Tablet test formulation 150mg(fed)

    Treatment E: During the study session, healthy subjects were administered a single dose of Olaparib Tablet test formulation 150mg under Fed conditions(test)

    Drug: Olaparib Tablet test formulation 150mg

  • Active comparator
    Olaparib Tablet reference formulation 150mg(fed)

    Treatment F: During the study session, healthy subjects were administered a single dose of Olaparib Tablet reference formulation 150mg under Fed conditions(reference for Treatment E)

    Drug: Olaparib Tablet reference formulation 150mg

Interventions

  • DrugOlaparib Tablet test formulation 100mg

    A generic product manufactured by CSPC Ouyi Pharmaceutical Co., Ltd.

  • DrugOlaparib Tablet reference formulation 100mg

    Olaparib Tablet reference formulation 100mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.

  • DrugOlaparib Tablet test formulation 150mg

    Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.

  • DrugOlaparib Tablet reference formulation 150mg

    Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.

This study also gives Olaparib. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Cmax Description: Maximum observed plasma concentration

    Cmax Description: Maximum observed plasma concentration

    Time frame: Up to 72 hours post-dose for each period

  2. AUC0-∞ Description: Area under the plasma concentration time curve from time zero extrapolated to infinite time

    AUC0-∞ Description: Area under the plasma concentration time curve from time zero extrapolated to infinite time

    Time frame: Up to 72 hours post-dose for each period

  3. AUC0-t Description: Area under the plasma concentration time curve from time zero to the time of the last quantifiable concentration

    AUC0-t Description: Area under the plasma concentration time curve from time zero to the time of the last quantifiable concentration

    Time frame: Up to 72 hours post-dose for each period

Secondary outcomes

  1. Time of maximum observed plasma concentration (Tmax)

    Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to 72 hours post-dose for each period

  2. Terminal elimination half-life (T1/2)

    Terminal elimination half-life (T1/2)

    Time frame: Up to 72 hours post-dose for each period

  3. Apparent total body clearance (Cl/F)

    Apparent total body clearance (Cl/F)

    Time frame: Up to 72 hours post-dose for each period

  4. Apparent volume of distribution (V/F)

    Apparent volume of distribution (V/F)

    Time frame: Up to 72 hours post-dose for eachperiod

  5. Number of participants with Adverse Events

    Number of participants with Adverse Events

    Time frame: Up to 10 days

07

Study locations

1 site
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing 100050, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Aug 2022, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2024
First posted
Apr 11, 2024
StartActual
May 26, 2022
Primary completionActual
Aug 21, 2022
CompletionActual
Aug 21, 2022
Last update
Apr 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06360445
Responsible party
Sponsor
First posted
Apr 11, 2024
Start date
May 26, 2022
Primary completion
Aug 21, 2022
Completion
Aug 21, 2022
Last update
Apr 11, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion